ArticleFrontiers in oncology2020
Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 47 citations in OpenAlex.
- The SUMO specific peptidase SENP3 promotes papillary thyroid cancer progression by deSUMOylation of SETDB1 and regulating GLI2 transcription.Clinical and experimental medicine · 2026Article
- Mechanisms and pathways of ROS and autophagy in thyroid cancer.Future science OA · 2025Review
- PROS1-MERTK Axis Drives Tumor Microenvironment Crosstalk and Progression in Papillary Thyroid Microcarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- EIF4A3-Induced Circ_0092278 Enhances Papillary Thyroid Cancer Cell Malignancy by the PI3K/Akt/mTOR Signaling Pathway.Journal of microbiology and biotechnology · 2025Article
- MicroRNA-mediated autophagy regulation in thyroid cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Effect and Safety of Apatinib as Neoadjuvant Therapy in Locally Advanced Differentiated Thyroid Cancer: A Phase 2 Trial.Journal of the Endocrine Society · 2024Article
- Therapeutic targeting of TNIK in papillary thyroid carcinoma: a novel approach for tumor growth suppression.Medical oncology (Northwood, London, England) · 2024Article
- Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.Medical oncology (Northwood, London, England) · 2023Review
- The new insights into autophagy in thyroid cancer progression.Journal of translational medicine · 2023Review
- Metastasis in Neuroblastoma and Its Link to Autophagy.Life (Basel, Switzerland) · 2023Review
- Low- dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer.Cancer medicine · 2023Article
- Article
- Non-Apoptotic Programmed Cell Death in Thyroid Diseases.Pharmaceuticals (Basel, Switzerland) · 2022Review
- AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour.World journal of surgical oncology · 2022Article
- Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma.Journal of cellular and molecular medicine · 2022Article
- Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.Cell death & disease · 2022Article
- To Explore the Inhibitory Mechanism of Quercetin in Thyroid Papillary Carcinoma through Network Pharmacology and Experiments.Disease markers · 2022Article
- Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma.Frontiers in endocrinology · 2022Article
- Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto's Thyroiditis.Frontiers in oncology · 2022Article
- Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 1 country.
Xiangrui MengKey Laboratory of Cancer Prevention and Therapy, Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Huijuan WangKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jingzhu ZhaoKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Linfei HuKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jingtai ZhiKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Songfeng WeiKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Xianhui RuanKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Xiukun HouKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Dapeng LiKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jun ZhangKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Weiwei YangDepartment of Otolaryngology-Head and Neck Surgery, Tianjin First Center Hospital, Tianjin, China.
Biyun QianDepartment of Epidemiology, School of Public Health, Shanghai Jiao Tong University, Shanghai, China.
Yu WuKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yuan ZhangDepartment of Head and Neck Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
Zhaowei MengDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China.
Lizhao GuanDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Huilai ZhangKey Laboratory of Cancer Prevention and Therapy, Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Xiangqian ZhengKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Ming GaoKey Laboratory of Cancer Prevention and Therapy, Department of Thyroid and Neck Tumor, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Tianjin Medical University Cancer Institute and Hospital · CNNanjing Medical University · CNShanghai Jiao Tong University · CNTianjin First Center Hospital · CNTianjin Medical University · CNTianjin Medical University General Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
apatinibapoptosisautophagypapillary thyroid carcinomaPI3K
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.